2. Metabolic Enzyme/Protease Protein Tyrosine Kinase/RTK JAK/STAT Signaling MAPK/ERK Pathway Stem Cell/Wnt Anti-infection
  3. Angiotensin-converting Enzyme (ACE) MMP EGFR ERK SARS-CoV
  4. JG26

JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases.

For research use only. We do not sell to patients.

JG26 Chemical Structure

JG26 Chemical Structure

CAS No. : 1464910-32-4

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

JG26 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE JG26

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases[1][2][3][4][5][6].

IC50 & Target[1]

ADAM17

1.9 nM (IC50)

MMP-12

9.4 nM (IC50)

ADAM8

12 nM (IC50)

ADAM10

150 nM (IC50)

MMP-8

240 nM (IC50)

MMP-9

1630 nM (IC50)

MMP14

19500 nM (IC50)

MMP-9

>500000 nM (IC50)

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
< 10 nM
Compound: 21
Inhibition of ADAM-17 in human A2780 cells assessed as inhibition of pervanadate-induced sALCAM release incubated for 30 mins prior to pervanadate induction measured after 90 mins by ELISA
Inhibition of ADAM-17 in human A2780 cells assessed as inhibition of pervanadate-induced sALCAM release incubated for 30 mins prior to pervanadate induction measured after 90 mins by ELISA
[PMID: 24044434]
A2780 IC50
845 nM
Compound: 21
Inhibition of ADAM-17 in human A2780 cells assessed as inhibition of EGF-induced sALCAM release incubated for 30 mins prior to EGF induction measured after 18 hrs by ELISA
Inhibition of ADAM-17 in human A2780 cells assessed as inhibition of EGF-induced sALCAM release incubated for 30 mins prior to EGF induction measured after 18 hrs by ELISA
[PMID: 24044434]
SK-OV-3 IC50
4272 nM
Compound: 21
Inhibition of ADAM-17 in human SKOV3 cells transfected with luciferase gene assessed as inhibition of EGF-induced sALCAM release incubated for 30 mins prior to EGF induction measured after 18 hrs by ELISA
Inhibition of ADAM-17 in human SKOV3 cells transfected with luciferase gene assessed as inhibition of EGF-induced sALCAM release incubated for 30 mins prior to EGF induction measured after 18 hrs by ELISA
[PMID: 24044434]
SK-OV-3 IC50
58 nM
Compound: 21
Inhibition of ADAM-17 in human SKOV3 cells transfected with luciferase gene assessed as inhibition of pervanadate-induced sALCAM release incubated for 30 mins prior to pervanadate induction measured after 90 mins by ELISA
Inhibition of ADAM-17 in human SKOV3 cells transfected with luciferase gene assessed as inhibition of pervanadate-induced sALCAM release incubated for 30 mins prior to pervanadate induction measured after 90 mins by ELISA
[PMID: 24044434]
In Vitro

JG26 (5-25 µM; 24-48 h) has no significant effect on the viability of Calu-3 cells (CC50: >25 µM) and increases the expression of ACE2 on the surface of Calu-3 cells[1].
JG26 (25 µM) can significantly reduce the infection of SARS-CoV-2 in Calu-3 cells, with LR values of 1.44 and 2.37, respectively[1].
JG26 (10 µM; 24 h) can reduce the shedding of NKG2D ligands in Hodgkin lymphoma cell lines[2].
JG26 (125 nM-10 µM; 24 h) can inhibit the cleavage of CD23 and the release of its soluble form in HEK293 cells[3].
JG26 (25 nM; 2 h) can effectively reduce the permeability of HUVECs and tumor cell adhesion induced by EMT-HCT116 exosomes[4].
JG26 (1 μM; 30 min) inhibits AngII-induced extracellular collagen accumulation in vascular smooth muscle cells (VSMCs)[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JG26 Related Antibodies
In Vivo

JG26 (3 mg/kg; i.v.) inhibits tumor metastasis in the orthotropic metastasis model of colorectal cancer (CRC) mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Six-week-old male athymic BALB/c-nu/nu mice, orthotropic metastasis model of colorectal cancer[4]
Dosage: 3 mg/kg
Administration: Intravenous injection
Result: Significantly reduced the decrease in VE-cadherin expression at the invasive front of CRC tumors.
Decreased the number of CTCs in mouse blood and the proportion of mice with both lung and liver metastasis.
Reduced the number and size of metastatic nodules in the lungs and liver.
Molecular Weight

594.27

Formula

C19H22Br2N4O6S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C([C@@H](CCCNC(N)=O)NS(=O)(C1=CC=C(C=C1)OCC2=CC(Br)=CC(Br)=C2)=O)NO
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (168.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6827 mL 8.4137 mL 16.8274 mL
5 mM 0.3365 mL 1.6827 mL 3.3655 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6827 mL 8.4137 mL 16.8274 mL 42.0684 mL
5 mM 0.3365 mL 1.6827 mL 3.3655 mL 8.4137 mL
10 mM 0.1683 mL 0.8414 mL 1.6827 mL 4.2068 mL
15 mM 0.1122 mL 0.5609 mL 1.1218 mL 2.8046 mL
20 mM 0.0841 mL 0.4207 mL 0.8414 mL 2.1034 mL
25 mM 0.0673 mL 0.3365 mL 0.6731 mL 1.6827 mL
30 mM 0.0561 mL 0.2805 mL 0.5609 mL 1.4023 mL
40 mM 0.0421 mL 0.2103 mL 0.4207 mL 1.0517 mL
50 mM 0.0337 mL 0.1683 mL 0.3365 mL 0.8414 mL
60 mM 0.0280 mL 0.1402 mL 0.2805 mL 0.7011 mL
80 mM 0.0210 mL 0.1052 mL 0.2103 mL 0.5259 mL
100 mM 0.0168 mL 0.0841 mL 0.1683 mL 0.4207 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JG26 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JG261464910-32-4JG 26JG-26Angiotensin-converting Enzyme (ACE)MMPEGFRERKSARS-CoVMatrix metalloproteinasesEpidermal growth factor receptorErbB-1HER1Extracellular signal regulated kinasesSARS coronavirusbreast cancerADAM17ADAM8CRCVSMCHUVECCalu-3Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JG26
Cat. No.:
HY-120852
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.